Status:
RECRUITING
DNA Analysis of Blood and Tissue from Patients with Lung Cancer
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lung Cancer
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It ma...
Detailed Description
OBJECTIVES: * Assess the role of genetic polymorphisms in lung-cancer risk in patients with lung cancer. * Assess the role of germline polymorphisms in DNA repair genes, p53 pathway genes, and a matr...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Patient:
- Newly diagnosed primary lung cancer
- Patient at Massachusetts General Hospital (MGH) or Boston Medical Center Cancer Center
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- Not specified
- EXCLUSIONS:
- Vulnerable populations are excluded. Patients with metastasis from another site to lung or mesothelioma are excluded.
Exclusion
Key Trial Info
Start Date :
September 1 2005
Trial Type :
OBSERVATIONAL
End Date :
September 1 2026
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00471978
Start Date
September 1 2005
End Date
September 1 2026
Last Update
November 29 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
2
Harvard School of Public Health
Boston, Massachusetts, United States, 02115